AZN
OtherAstrazeneca plc
$184.92+3.68 (+2.03%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AZN Today?
No stock-specific AI insight has been generated for AZN yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$286.8B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding1.55B
AZN News
50 articles- Ironwood Stock Down Despite Q1 Earnings and Revenue BeatYahoo Finance·May 8, 2026
- AstraZeneca’s RNA Research Push Meets Valuation Gap In Investor FocusYahoo Finance·May 8, 2026
- Oblique Therapeutics today announced that Dr. Jan Lundberg has joined the company as Scientific AdvisorYahoo Finance·May 8, 2026
- Darzalex, Erleada & New Drugs Keep J&J's Oncology Engine Charged in Q1Yahoo Finance·May 7, 2026
- Why This Income Pro Likes Banks, Chip-Equipment Companies, and MoreYahoo Finance·May 7, 2026
- The AI Summit London Unveils 10th Anniversary Speaker Line-Up Featuring Global Leaders in Enterprise AIYahoo Finance·May 7, 2026
- Ken Fisher's Strategic Moves: AstraZeneca PLC Leads the Portfolio AdditionsYahoo Finance·May 6, 2026
- Global RNA Targeting Small Molecule Drug Discovery Market Size/Share Worth USD 17.6 Billion by 2035 at a 22.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)Yahoo Finance·May 6, 2026
- 6 Pharma Dividend Stocks Yielding Up to 6.44% — and They’ve Survived Every Market Crash247 Wall St·May 6, 2026
- CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering DiscussionsYahoo Finance·May 6, 2026
- Medable CEO Michelle Longmire Featured as Guest Speaker with Leaders from Google and Mayo Clinic at Japan’s Largest Pharmaceutical SummitYahoo Finance·May 6, 2026
- SOPHiA GENETICS Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?Yahoo Finance·May 4, 2026
- Strong Results and Improved Guidance Lifted AstraZeneca PLC (AZN)Yahoo Finance·May 4, 2026
- Mixed FDA Votes On Truqap And Camizestrant Refocus AstraZeneca Oncology RiskYahoo Finance·May 4, 2026
- Is Mineralys Therapeutics, Inc. (MLYS) A Good Stock To Buy Now?Yahoo Finance·May 3, 2026
- Is AstraZeneca PLC (AZN) A Good Stock To Buy Now?Yahoo Finance·May 3, 2026
- The 28th China Beijing International High-Tech Expo Grand Opening SoonYahoo Finance·May 2, 2026
- Amgen's Q1 Earnings Top Estimates, 16 Drugs Deliver Double-Digit GainsYahoo Finance·May 1, 2026
- Summit’s ‘self-inflicted’ stumble; Esperion’s take-private dealBiopharmadive·May 1, 2026
- IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsightGlobeNewswire Inc.·Apr 29, 2026
- FDA Announces Major Steps to Implement Real-Time Clinical TrialsGlobeNewswire Inc.·Apr 28, 2026
- Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobeNewswire Inc.·Apr 28, 2026
- Antibiotic Resistance Market to Grow at 5.4% CAGR Reaching USD 12.72 Billion by 2031, Driven by Rising Drug-Resistant Infections and Antimicrobial Innovation: Mordor IntelligenceGlobeNewswire Inc.·Apr 28, 2026
- AI Disruption in Lung Cancer Therapeutics Set to Transform Treatment Paradigms as Billion-Dollar Investments Drive InnovationGlobeNewswire Inc.·Apr 27, 2026
- Clinical Trial Software Research Report 2026: $2.5+ Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FGlobeNewswire Inc.·Apr 24, 2026
- Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsightGlobeNewswire Inc.·Apr 23, 2026
- Vulvar Cancer Market Global and Regional Analysis Report 2025-2035, Profiles of Merck & Co., Bristol Myers Squibb, and AstraZenecaGlobeNewswire Inc.·Apr 22, 2026
- Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsightGlobeNewswire Inc.·Apr 21, 2026
- Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - Clinical Trials, Regulatory Approvals, Development PlatformsGlobeNewswire Inc.·Apr 21, 2026
- Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & OutlookGlobeNewswire Inc.·Apr 21, 2026
- Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsightGlobeNewswire Inc.·Apr 16, 2026
- Alethio Therapeutics Unveils ATX‑011, a Breakthrough, Mutation‑Agnostic Antibody for Treating Essential Thrombocythemia – a c.$2B Market, and Strengthens Leadership to Accelerate Path to INDGlobeNewswire Inc.·Apr 16, 2026
- Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsightGlobeNewswire Inc.·Apr 15, 2026
- AIM ImmunoTech Provides Routine Update on Annual FilingsGlobeNewswire Inc.·Apr 13, 2026
- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsightGlobeNewswire Inc.·Apr 13, 2026
- $5.14 Bn Castration-sensitive Prostate Cancer Market Insights, Epidemiology, and Forecasts, 2022-2026 & 2026-2036GlobeNewswire Inc.·Apr 13, 2026
- 7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing TreatmentsGlobeNewswire Inc.·Apr 10, 2026
- Severe Asthma Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsightGlobeNewswire Inc.·Apr 7, 2026
- Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsightGlobeNewswire Inc.·Apr 6, 2026
Price Data
Open$184.36
Previous Close$181.24
Day High$185.19
Day Low$182.80
52 Week High—
52 Week Low—
Fundamentals
Market Cap$286.8B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding1.55B
About Astrazeneca plc
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SIC—
CIK—
Composite FIGI—
Share Class FIGI—